X4 Pharmaceuticals (NASDAQ:XFOR) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.03), Zacks reports. The company had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.07 million.

X4 Pharmaceuticals Stock Down 7.8 %

Shares of XFOR traded down $0.02 during trading hours on Friday, reaching $0.25. The company's stock had a trading volume of 1,548,728 shares, compared to its average volume of 2,843,188. The company has a 50 day moving average of $0.43 and a two-hundred day moving average of $0.52. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The firm has a market cap of $43.42 million, a price-to-earnings ratio of -2.78 and a beta of 0.39. X4 Pharmaceuticals has a 1-year low of $0.24 and a 1-year high of $1.60.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 76,473 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the sale, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. This represents a 6.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. Over the last three months, insiders sold 202,663 shares of company stock worth $91,198. 1.62% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in X4 Pharmaceuticals stock. Bank of America Corp DE lifted its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 20.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 133,502 shares of the company's stock after purchasing an additional 22,485 shares during the period. Bank of America Corp DE owned 0.08% of X4 Pharmaceuticals worth $98,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 72.03% of the company's stock.

Analyst Ratings Changes

XFOR has been the subject of several recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $3.00 target price on shares of X4 Pharmaceuticals in a report on Wednesday. HC Wainwright reaffirmed a "buy" rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a research note on Thursday.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.